Literature DB >> 11526532

A comparative study of antibody expressions in primary biliary cirrhosis and autoimmune cholangitis using phage display.

N Ikuno1, M Scealy, J M Davies, S F Whittingham, K Omagari, I R Mackay, M J Rowley.   

Abstract

Primary biliary cirrhosis (PBC) and autoimmune cholangitis (AIC) are serologic expressions of an autoimmune liver disease affecting biliary ductular cells. Previously we screened a phage-displayed random peptide library with polyclonal IgG from 2 Australian patients with PBC and derived peptides that identified a single conformational (discontinuous) epitope in the inner lipoyl domain of the E2 subunit of the pyruvate dehydrogenase complex (PDC-E2), the characteristic autoantigen in PBC. Here we have used phage display to investigate the reactivity of PBC sera from 2 ethnically and geographically distinct populations, Japanese and Australian, and the 2 serologic expressions, PBC and AIC. Random 7-mer and 12-mer peptide libraries were biopanned with IgG from 3 Japanese patients with PBC and 3 with AIC who did not have anti-PDC-E2. The phage clones (phagotopes) obtained were tested by capture enzyme-linked immunosorbent assay (ELISA) for reactivity with affinity-purified anti-PDC-E2, and compared with those obtained from Australian patients with PBC. Peptide sequences of the derived phagotopes and sequences derived by biopanning with irrelevant antisera were aligned to develop a guide tree based on physicochemical similarity. Both Australian and Japanese PBC-derived phagotopes were distributed in branches of the guide tree that contained the peptide sequences MH and FV previously identified as part of an immunodominant conformational epitope of PDC-E2, indicating that epitope selection was not influenced by the racial origin of the PBC sera. Biopanning with either PBC or AIC-derived IgG yielded phagotopes that reacted with anti-PDC-E2 by capture ELISA, further establishing that there is a similar autoimmune targeting in PBC and AIC.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11526532     DOI: 10.1053/jhep.2001.27013

Source DB:  PubMed          Journal:  Hepatology        ISSN: 0270-9139            Impact factor:   17.425


  7 in total

Review 1.  Phage display--a powerful technique for immunotherapy: 1. Introduction and potential of therapeutic applications.

Authors:  Justyna Bazan; Ireneusz Całkosiński; Andrzej Gamian
Journal:  Hum Vaccin Immunother       Date:  2012-08-21       Impact factor: 3.452

2.  Generation of a cholangiocyte-specific cDNA expression library for the identification of B and T cell autoantigens in murine biliary disease.

Authors:  Rebecca M Tucker; Cara L Mack
Journal:  Hepatol Res       Date:  2012-01-11       Impact factor: 4.288

3.  Characterization of M2 antibodies in asymptomatic Chinese population.

Authors:  Xiao-Hua Jiang; Ren-Qian Zhong; Xiao-Yun Fan; Yin Hu; Feng An; Jian-Wen Sun; Xian-Tao Kong
Journal:  World J Gastroenterol       Date:  2003-09       Impact factor: 5.742

4.  Survival of anti-mitochondrial antibody-positive and -negative primary biliary cirrhosis patients on ursodeoxycholic acid treatment.

Authors:  Meri Koulentaki; Joanna Moscandrea; Philipos Dimoulios; Costas Chatzicostas; Elias A Kouroumalis
Journal:  Dig Dis Sci       Date:  2004-08       Impact factor: 3.199

Review 5.  Overlap syndromes among autoimmune liver diseases.

Authors:  Christian Rust; Ulrich Beuers
Journal:  World J Gastroenterol       Date:  2008-06-07       Impact factor: 5.742

6.  Construction and expression of a humanized M2 autoantigen trimer and its application in the diagnosis of primary biliary cirrhosis.

Authors:  Xiao-Hua Jiang; Ren-Qian Zhong; Sheng-Qian Yu; Yin Hu; Weng-Weng Li; Xian-Tao Kong
Journal:  World J Gastroenterol       Date:  2003-06       Impact factor: 5.742

7.  Identification of conformational epitopes for human IgG on Chemotaxis inhibitory protein of Staphylococcus aureus.

Authors:  Erika Gustafsson; Pieter-Jan Haas; Björn Walse; Marcel Hijnen; Christina Furebring; Mats Ohlin; Jos A G van Strijp; Kok P M van Kessel
Journal:  BMC Immunol       Date:  2009-03-11       Impact factor: 3.615

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.